---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-064025"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:17:59.016847+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid

## Summary
- Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.
- Monotherapy: 1 CR (mucoepidermoid parotid, 71 wks), 2 PRs (endometrial), 9 SD ≥18 wks; clinical benefit rate 41.4%.
- Safety profile well tolerated; most TRAEs grade 1/2; no treatment-related deaths.
- Based on data, expansion cohorts in NSCLC initiated; Phase 1 in relapsed/refractory multiple myeloma planned.
- Data to be presented at ASCO 2024 on June 3; investor event June 1.

## SEC filing metadata
- accession: 0000950170-24-064025
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024064025/0000950170-24-064025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024064025/cgem-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-064025
- JSON: https://secwatch.observer/filing/0000950170-24-064025.json
- Plain text: https://secwatch.observer/filing/0000950170-24-064025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.